Please enable JavaScript to continue using this application.

Compare $GNLX vs $HUMA | Chartloom

Compare

$GNLX vs $HUMA

Genelux Corp · Humacyte Inc

GNLX

Genelux Corp

HUMA

Humacyte Inc

Compare $GNLX vs $HUMA

Comparing Genelux Corp and Humacyte Inc

GNLXGenelux Corp

HUMAHumacyte Inc

GNLXGenelux Corp

Market cap

$115M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-43.7%

52W performance

-46.1%

FCF yield

-25.0%

HUMAHumacyte Inc

Market cap

$109M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.62x

Rev growth (TTM)

159.3%

YTD performance

-58.4%

52W performance

-76.0%

FCF yield

-89.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GNLX

HUMA

Detailed metrics comparison

GNLX

Genelux Corp

HUMA

Humacyte Inc

Market Cap

GNLX$115M

HUMA$109M

Enterprise Value

GNLX$106M

HUMA$96M

Price

GNLX$2.56

HUMA$0.41

P/E Ratio

GNLXN/A

HUMAN/A

P/S Ratio

GNLX14,348.80x

HUMA51.53x

EV/Sales

GNLX13,200.80x

HUMA45.06x

EV/EBITDA

GNLX0.00x

HUMA0.00x

P/B Ratio

GNLX7.19x

HUMA4.63x

P/FCF Ratio

GNLXN/A

HUMAN/A

EV/FCF

GNLX-3.68x

HUMA-0.98x

PEG Ratio

GNLXN/A

HUMAN/A

Forward P/E (NTM)

GNLXN/A

HUMAN/A

Forward P/S (NTM)

GNLXN/A

HUMA14.62x

Revenue (TTM)

GNLX$8K

HUMA$2M

Revenue Growth (YoY)

GNLXN/A

HUMA159.3%

Forward Rev Growth

GNLX551.6%

HUMA520.3%

Gross Margin (TTM)

GNLX0.0%

HUMA-494.6%

Operating Margin (TTM)

GNLX0.0%

HUMA0.0%

EBITDA Margin (TTM)

GNLX-453500.0%

HUMA-4900.0%

Net Margin (TTM)

GNLX-444950.0%

HUMA-4560.8%

FCF Margin (TTM)

GNLX-358537.5%

HUMA-4599.7%

Net Income (TTM)

GNLX$-36M

HUMA$-97M

FCF (TTM)

GNLX$-29M

HUMA$-98M

EPS (TTM)

GNLX-$0.79

HUMA-$0.41

ROE (TTM)

GNLX-20585.0%

HUMA-51675.0%

ROA (TTM)

GNLX-13879.0%

HUMA-8476.0%

ROIC (TTM)

GNLX-20585.0%

HUMA-9784.0%

Cash

GNLX$9M

HUMA$80M

Debt

GNLX$0

HUMA$66M

Net Cash/Debt

GNLX$9M

HUMA$14M

Current Ratio (TTM)

GNLX2.39x

HUMA6.21x

Quick Ratio (TTM)

GNLX2.33x

HUMA5.38x

Debt/Equity (TTM)

GNLX0.00x

HUMA2.12x

Debt/Assets (TTM)

GNLX0.0%

HUMA0.0%

Interest Coverage (TTM)

GNLXN/A

HUMAN/A

Net Debt/EBITDA (TTM)

GNLX0.00x

HUMA0.00x

Beta

GNLX0.56

HUMA2.76

52W Performance

GNLX-46.1%

HUMA-76.0%

YTD Performance

GNLX-43.7%

HUMA-58.4%

% from 52W High

GNLX-70.0%

HUMA-78.6%

% from 52W Low

GNLX11.8%

HUMA3.7%

Asset Turnover (TTM)

GNLX0.00x

HUMA0.02x

FCF Yield (TTM)

GNLX-25.0%

HUMA-89.3%

Earnings Yield (TTM)

GNLX-31.0%

HUMA-88.5%

Dividend Yield (TTM)

GNLXN/A

HUMAN/A

Rule of 40

GNLX-358,537.5

HUMA-4,440.4

EV/GP/RG

GNLXN/A

HUMAN/A

Ticker research

View GNLX research View HUMA research

Metric	GNLX Genelux Corp	HUMA Humacyte Inc
Market & Valuation
Market Cap	$115M	$109M
Enterprise Value	$106M	$96M
Price	$2.56	$0.41
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	51.53x
EV/Sales	13,200.80x	45.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	4.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-0.98x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	14.62x
Revenue & Growth
Revenue (TTM)	$8K	$2M
Revenue Growth (YoY)	N/A	159.3%
Forward Rev Growth	551.6%	520.3%
Profitability
Gross Margin (TTM)	0.0%	-494.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-453500.0%	-4900.0%
Net Margin (TTM)	-444950.0%	-4560.8%
FCF Margin (TTM)	-358537.5%	-4599.7%
Net Income (TTM)	$-36M	$-97M
FCF (TTM)	$-29M	$-98M
EPS (TTM)	-$0.79	-$0.41
ROE (TTM)	-20585.0%	-51675.0%
ROA (TTM)	-13879.0%	-8476.0%
ROIC (TTM)	-20585.0%	-9784.0%
Financial Health
Cash	$9M	$80M
Debt	$0	$66M
Net Cash/Debt	$9M	$14M
Current Ratio (TTM)	2.39x	6.21x
Quick Ratio (TTM)	2.33x	5.38x
Debt/Equity (TTM)	0.00x	2.12x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	2.76
52W Performance	-46.1%	-76.0%
YTD Performance	-43.7%	-58.4%
% from 52W High	-70.0%	-78.6%
% from 52W Low	11.8%	3.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-25.0%	-89.3%
Earnings Yield (TTM)	-31.0%	-88.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	-4,440.4
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View HUMA research

Valuation

P/S Ratio

HUMA

51.53x

GNLX

14,348.80x

EV/FCF

GNLX

-3.68x

HUMA

-0.98x

Growth & revenue

Revenue Growth TTM

HUMA

159.3%

Forward Revenue Growth

GNLX

551.6%

HUMA

520.3%

Profitability & performance

Gross Margin

GNLX

0.0%

HUMA

-494.6%

ROE

GNLX

-20585.0%

HUMA

-51675.0%

FCF Yield %

GNLX

-25.0%

HUMA

-89.3%

52-Week Performance

GNLX

-46.1%

HUMA

-76.0%

Detailed metrics comparison

GNLX

Genelux Corp

HUMA

Humacyte Inc

Market Cap

GNLX$115M

HUMA$109M

Enterprise Value

GNLX$106M

HUMA$96M

Price

GNLX$2.56

HUMA$0.41

P/E Ratio

GNLXN/A

HUMAN/A

P/S Ratio

GNLX14,348.80x

HUMA51.53x

EV/Sales

GNLX13,200.80x

HUMA45.06x

EV/EBITDA

GNLX0.00x

HUMA0.00x

P/B Ratio

GNLX7.19x

HUMA4.63x

P/FCF Ratio

GNLXN/A

HUMAN/A

EV/FCF

GNLX-3.68x

HUMA-0.98x

PEG Ratio

GNLXN/A

HUMAN/A

Forward P/E (NTM)

GNLXN/A

HUMAN/A

Forward P/S (NTM)

GNLXN/A

HUMA14.62x

Revenue (TTM)

GNLX$8K

HUMA$2M

Revenue Growth (YoY)

GNLXN/A

HUMA159.3%

Forward Rev Growth

GNLX551.6%

HUMA520.3%

Gross Margin (TTM)

GNLX0.0%

HUMA-494.6%

Operating Margin (TTM)

GNLX0.0%

HUMA0.0%

EBITDA Margin (TTM)

GNLX-453500.0%

HUMA-4900.0%

Net Margin (TTM)

GNLX-444950.0%

HUMA-4560.8%

FCF Margin (TTM)

GNLX-358537.5%

HUMA-4599.7%

Net Income (TTM)

GNLX$-36M

HUMA$-97M

FCF (TTM)

GNLX$-29M

HUMA$-98M

EPS (TTM)

GNLX-$0.79

HUMA-$0.41

ROE (TTM)

GNLX-20585.0%

HUMA-51675.0%

ROA (TTM)

GNLX-13879.0%

HUMA-8476.0%

ROIC (TTM)

GNLX-20585.0%

HUMA-9784.0%

Cash

GNLX$9M

HUMA$80M

Debt

GNLX$0

HUMA$66M

Net Cash/Debt

GNLX$9M

HUMA$14M

Current Ratio (TTM)

GNLX2.39x

HUMA6.21x

Quick Ratio (TTM)

GNLX2.33x

HUMA5.38x

Debt/Equity (TTM)

GNLX0.00x

HUMA2.12x

Debt/Assets (TTM)

GNLX0.0%

HUMA0.0%

Interest Coverage (TTM)

GNLXN/A

HUMAN/A

Net Debt/EBITDA (TTM)

GNLX0.00x

HUMA0.00x

Beta

GNLX0.56

HUMA2.76

52W Performance

GNLX-46.1%

HUMA-76.0%

YTD Performance

GNLX-43.7%

HUMA-58.4%

% from 52W High

GNLX-70.0%

HUMA-78.6%

% from 52W Low

GNLX11.8%

HUMA3.7%

Asset Turnover (TTM)

GNLX0.00x

HUMA0.02x

FCF Yield (TTM)

GNLX-25.0%

HUMA-89.3%

Earnings Yield (TTM)

GNLX-31.0%

HUMA-88.5%

Dividend Yield (TTM)

GNLXN/A

HUMAN/A

Rule of 40

GNLX-358,537.5

HUMA-4,440.4

EV/GP/RG

GNLXN/A

HUMAN/A

Ticker research

View GNLX research View HUMA research

Metric	GNLX Genelux Corp	HUMA Humacyte Inc
Market & Valuation
Market Cap	$115M	$109M
Enterprise Value	$106M	$96M
Price	$2.56	$0.41
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	51.53x
EV/Sales	13,200.80x	45.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	4.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-0.98x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	14.62x
Revenue & Growth
Revenue (TTM)	$8K	$2M
Revenue Growth (YoY)	N/A	159.3%
Forward Rev Growth	551.6%	520.3%
Profitability
Gross Margin (TTM)	0.0%	-494.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-453500.0%	-4900.0%
Net Margin (TTM)	-444950.0%	-4560.8%
FCF Margin (TTM)	-358537.5%	-4599.7%
Net Income (TTM)	$-36M	$-97M
FCF (TTM)	$-29M	$-98M
EPS (TTM)	-$0.79	-$0.41
ROE (TTM)	-20585.0%	-51675.0%
ROA (TTM)	-13879.0%	-8476.0%
ROIC (TTM)	-20585.0%	-9784.0%
Financial Health
Cash	$9M	$80M
Debt	$0	$66M
Net Cash/Debt	$9M	$14M
Current Ratio (TTM)	2.39x	6.21x
Quick Ratio (TTM)	2.33x	5.38x
Debt/Equity (TTM)	0.00x	2.12x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	2.76
52W Performance	-46.1%	-76.0%
YTD Performance	-43.7%	-58.4%
% from 52W High	-70.0%	-78.6%
% from 52W Low	11.8%	3.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-25.0%	-89.3%
Earnings Yield (TTM)	-31.0%	-88.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	-4,440.4
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View HUMA research